Drug discovery

#Analysis #Drug discovery #RNA #Stem cells #Therapeutics

Advanced BioMatrix Acquires HyStem from Lineage Cell Therapeutics

Advanced BioMatrix has acquired the HyStem line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan. HyStem® kits are based on innovative thiolated hyaluronic acid technology. With HyStem®, researchers can create customizable 3D hydrogels for culturing cells whose natural environment is rich in hyaluronic acid. Read More

#News

#Biobanking #Business #Drug development #Drug discovery #Genomics #Lead discovery

TTP Labtech Announces Company Name Change to SPT Labtech

TTP Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science applications, has announced its corporate name change to SPT Labtech effective from January 6, 2020. The change of name is a contractual requirement of its divestment from… Read More

#News

#Drug development #Drug discovery #Drug targets #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Protein chemistry / Proteomics #RNA #Stem cells #Therapeutics #Translational #Translational chemistry

Pathios Therapeutics closes US$8.8M Series A and appoints Stuart Hughes as CEO

The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More

#News

#Cell therapy #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Oncology #RNA #Stem cells #System biology #Therapeutics

Grey Wolf completes financing to accelerate development of ERAP2 therapies

Grey Wolf Therapeutics completes £2.5 million ($3.3 million) Series A2 financing to accelerate development of therapies targeting ERAP2. Grey Wolf targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumors for attack and destruction by the immune system. Grey Wolf Therapeutics, a drug discovery… Read More

#News

#Biochemistry #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Drug development #Drug discovery #Gene therapy #Lead discovery #RNA #Therapeutics

Enterprise Therapeutics publishes paper on novel cystic fibrosis approach

Enterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients. Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of… Read More

#News

#Academic #Analysis #Assay development optimisation & technology #Cellular assays #Drug development #Drug discovery #Lead discovery #Lead optimisation #Preclinical #RNA #Screening #Target validation #Toxicology

Arctoris Ltd Successfully Moves into its New Global Headquarters in Oxford, UK

State-of-the art facility is home to the company’s next-generation, fully automated platform for drug discovery. Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford,… Read More

#News

#Drug discovery

ABPI responds to UK Brexit medicine stockpiling guidance

The UK’s Department of Health and Social Care has published a letter setting out its government’s plan and requests of industry and the wider supply chain ahead of the end of the Brexit transition period. This aims to help ensure the continuity of supply of medical goods into… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology #Immunology / Virology & Vaccines #Pathology #Preclinical #RNA

NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies

The vaccine is currently being evaluated in Phase 3 clinical testing. The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Cell therapy #Drug development #Drug discovery #Gene therapy #Immunology #Lead discovery #Oncology #Pathology #Precision medicine #RNA #Screening #Stem cells #Therapeutics

Researchers discover cell communication mechanism that drives cancer adaptation

Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies. This mechanism involves cells releasing small vesicles, known as exosomes. These contain complex mixtures of proteins,… Read More

#Cancer Research #Covid-19 #News

#AI / data analytics / healthtech / informatics #Business #Drug discovery #Target validation

Thermo Fisher expands options for SampleManager LIMS

Thermo Fisher Scientific has expanded available options for SampleManager LIMS software, offering laboratories end-to-end support of the software deployment in the Amazon Web Services (AWS) Cloud. Under a contract agreement, Thermo Fisher will manage the process from installation and maintenance to backup and recovery. Labs will benefit from… Read More

#News

#Business #Drug development #Drug discovery #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Preclinical #Regulatory #Stem cells

Cancer Research UK collaborate to develop head and neck cancer vaccine

This a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC) HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Business #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Molecular medicine #Orphan drugs #Precision medicine

Centogene and Molecular Health collaborate to develop orphan drugs

Image: Fabio Centogene and Molecular Health, are to collaborate on the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project, starting with epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based… Read More

#News

#Academic #Business #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Drug target for aggressive breast cancer found

A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously… Read More

#Cancer Research #News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

Phase III clinical trial of investigational vaccine for COVID-19 begins in US

Multi-site trial to test candidate developed by Moderna and NIH. A Phase III clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna and… Read More

#Covid-19 #News

#Academic #Business #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK government advises drug companies to stockpile in case of Brexit disruption

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer,… Read More

#Covid-19 #News

#Automation / robotics #Business #Drug discovery

SLAS2021 goes digital

Image: Rodion Kutsaev SLAS2021 will now be a fully digital experience as well as a celebration of 10 years of laboratory automation, scientific education and innovation. The event will be free for SLAS Premier Members and students with registration opening in October. Advantages of SLAS2021 Digital: More members of… Read More

#News